Telehealth Growth Desk: Q1 2026 Brief

The Telehealth Growth Desk is a short quarterly brief for cash-pay clinics. It is educational, not legal or medical advice.

Four things in Q1 2026 changed the math for a cash-pay clinic: a pill hit the market, two federal clocks got pushed out, Medicare's plans for GLP-1 coverage took shape and the FDA put 30 telehealth companies on notice about how they talk. Here is the brief, newest items last, with what each one means and what I would do about it in Q2.

What changed in Q1 2026?

Six items, in date order, picking up where the 2025 review left off.

January 1: DEA prescribing flexibilities extended again

Frier Levitt reported a fourth temporary extension of the COVID-era rule, scheduled for publication on December 31, 2025, that allows prescribing of Schedule II to V controlled substances via telemedicine without a prior in-person evaluation, provided the rule's conditions are met, through December 31, 2026.¹ McDermott adds that the DEA says the extension avoids a "telemedicine cliff" and gives it time to finalize a permanent rule. The proposed special registration framework remains unfinalized, and it is unclear how the agency will proceed.² I walked through the dates in DEA Telemedicine Flexibilities Through 2026.

January 5: the Wegovy pill launches

Novo Nordisk said the pill was broadly available across America, at more than 70,000 pharmacies and through named telehealth providers including Ro, LifeMD and Weight Watchers. The 1.5 mg starting dose was $149 per month on its self-pay offer, and the 4 mg dose was $149 through April 15, 2026 and $199 afterward, with the highest doses at $299.³ I covered the approval itself in Oral Wegovy Is Approved.

January 7: the Medicare GLP-1 plan takes shape

McDermott reported that, without amending coverage rules, CMS planned to use two demonstrations to begin Medicare coverage of GLP-1 medications for members with obesity and related comorbidities in April 2026, with pricing of $245 per month and copays capped at $50.⁴ The firm warned that telehealth platforms competing on price may see their cost advantage narrow. I have not seen confirmation of how the April start went, so check status before you plan around it.

February 3: Medicare telehealth flexibilities extended through 2027

The Consolidated Appropriations Act, H.R. 7148, signed on February 3, extends key Medicare telehealth flexibilities through December 31, 2027. Frier Levitt notes the extension is temporary, that it does not override state-specific requirements and that clinics should keep reviewing billing, licensure, controlled substance prescribing and privacy.⁵

March 3: 30 FDA warning letters

The FDA announced warning letters to 30 telehealth companies over illegal marketing of compounded GLP-1s, and reminded the market that compounded products are neither approved nor equivalent to approved generics.⁶ Foley's summary lists the kinds of statements that drew letters: "generic Zepbound," "contains the active pharmaceutical ingredient in Wegovy," "FDA-approved" implications and claims that a product was "clinically studied." It also stresses contracts that allocate compliance duties among platforms and pharmacies.⁷

April 1: the FDA clarifies compounding policy

Foley reports that the FDA's statement defines when a compounded GLP-1 is "essentially a copy" of a commercial product, says it does not currently intend to act against a 503A compounder filling four or fewer prescriptions of an essentially-a-copy product in a month, and notes that semaglutide and tirzepatide are on neither the 503B bulks list nor the shortage list. The statement is a policy clarification that "does not have the force and effect of law."⁸

What does this mean for a cash-pay clinic?

Read the items together, not one at a time.

Price is now a public conversation

With a pill at $149 for its starting dose and manufacturer and government price points in public view, a clinic cannot hide behind opaque pricing, because price is now a public conversation. Compete on process and service, and keep every published price current with a dated source.

Ro CEO Zach Reitano described the shift this way in an interview posted on March 23, 2026. He runs a company that sells these drugs, so read it as a CEO's view, not a market statistic.⁹

Plays here, from YouTube

Whether or not he is right about the share, the operating point for a clinic is the same: cash prices are public, and your offer has to stand next to them.

The marketing risk moved from fringe to center

Before March, strong language about compounded products could feel like a gray area. After the letters, the language the FDA singled out reads like a checklist. If your pages say a product has "the same active ingredient" as a brand or call it "generic," fix it now, with counsel.

Regulatory clocks are your planning horizon

The DEA extension runs through December 31, 2026, and Medicare telehealth flexibilities run through December 31, 2027. Neither is permanent. If your service line depends on either, put the expiry dates on your calendar and decide now what you would do if they were not extended.

What are the Q2 priorities?

Five, in order.

What I am watching in Q2

Three things. Whether the FDA follows its March letters with more. Whether the Medicare GLP-1 coverage plan starts as described and what it does to cash-pay demand. And whether the DEA moves on a permanent telemedicine rule before the extension runs out.

I have built revenue systems for telehealth brands. The clinics that do well in an uncertain year are not the ones who guess right about policy. They are the ones who built their business to survive either answer.

This article is educational and is not legal advice. Talk to a qualified healthcare attorney about your situation.

Keep building.Ekai